The race for dominance in the multi-billion-dollar immune-oncology market has caused multi-billion-dollar swings in the market caps of two leading competitors

Specialty pharmaceutical firms such as Mallinckrodt have taken a beating over the past two years

AstraZeneca's shares have languished since the company fought off a Pfizer acquisition attempt

UnitedHealth shares fell even though earnings beat expectations as investors expressed skittishness about Trump-related uncertainty

Donald Trump's drug pricing comments put a damper on a nice start to the year for biotech stocks

Valeant shares got as much as a 14 percent pop on the news the company finally managed to divest some assets

Takeda's deal bails out Ariad shareholders, who have had a rocky ride over the past few years

Biotech trailed the broader stock market by a wide margin throughout 2016

GlaxoSmithKline has the highest dividend yield of its European peers

Pricing scrutiny and disappointing results have weighed on large pharma stocks this year

Biogen's choice of new CEO is getting tepid market reviews

Gilead's shares have underperformed the rest of biotech as its hepatitis C sales have slowed

Some tough times in its diabetes business and the prominent failure of a drug intended to treat Alzheimer's have Lilly shares underperforming peers

Bluebird Bio's share price rose on positive scientific news this week, but fell with the rest of the industry after Donald Trump said he wanted to bring drug prices down